Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients.
To investigate the interaction of fluconazole and zidovudine in HIV-positive non-smoking male patients with AIDS categorized as CDC group IV we studied two groups, each consisting of 10 male, non-smoking, HIV-positive patients with CDC group IV disease, with the patients in the first group additionally suffering from candida esophagitis. In the first group, the pharmacokinetics of 500 mg oral zidovudine were determined both before and after 7 days of treatment with fluconazole 400 mg/d. In the second group, the pharmacokinetics of 200 mg oral fluconazole were determined before and after 14 days of treatment with zidovudine 4 x 250 mg/d. In order to determine the microsomal enzyme activity, the 6-beta-hydroxycortisol/17-hydroxycorticosteroid ratio and antipyrine pharmacokinetic parameters were determined. 6-beta-hydroxycortisol was quantitated by RIA. The 17-hydroxycorticosteroids were determined by a colorimetric method. Zidovudine (ZDV) and zidovudine glucuronide (GZDV), and the fluconazole and antipyrine plasma and urine concentrations were measured by HPLC. Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole). No changes were found in the GZDV plasma kinetics and the ZDV and GZDV urinary excretion. Treatment with ZDV did not have any impact on the half-life of fluconazole. Administration of zidovudine did, however, result in a significant reduction in antipyrine half-life (11.7 +/- 2.0 h before vs. 9.9 +/- 2.3h after ZDV) and a significant increase in 6-beta-hydroxycortisol excretion (438,7 +/- 138.2 microg/24 h before and 684.6 +/- 157.3 microg/24 h after ZDV). Since the antipyrine clearance is altered after administration of ZDV, it is assumed that zidovudine induces cytochrome P450 enzymes. This effect, however, does not alter the pharmacokinetics of fluconazole. High doses of fluconazole can inhibit the plasma elimination of both antipyrine and zidovudine, but the extent of this inhibitory effect is so small that no clinically relevant accumulation is to be expected.
Brockmeyer
N H
NH
Universität Essen, Klinik für Dermatologie, Venerologie und Allergologie, Hufelandstr. 55, Essen D-45147, Germany. dermatology@uni-essen.de
Tillmann
I
I
Mertins
L
L
Barthel
B
B
Goos
M
M
D015065:17-Hydroxycorticosteroids / Q000652:urine; D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000378:metabolism; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000378:metabolism*; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000983:Antipyrine / Q000493:pharmacokinetics; D002180:Candidiasis, Oral / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015725:Fluconazole / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D006854:Hydrocortisone / Q000031:analogs & derivatives / Q000652:urine; D008297:Male; D015215:Zidovudine / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000493:pharmacokinetics*
D015065:17-Hydroxycorticosteroids; D019380:Anti-HIV Agents; D000935:Antifungal Agents; D015215:Zidovudine; C001380:6 beta-hydroxycortisol; D015725:Fluconazole; C055886:3'-azido-3'-deoxy-5'-O-beta-glucopyranuronosylthymidine; D000983:Antipyrine; D006854:Hydrocortisone